Skip to main content
OpenTrials
Completed

NCT Number: NCT03775499

Probiotic BL NCC 2705 and Gluten Sensitivity

The aim of the study is to confirm/prove safety of the probiotic and production of serpin in humans.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Viecuri Hospital

Venlo, Netherlands

About this study

This trial is a multicenter, double blind, randomized, placebo controlled, 2 by 2 cross-over design (i.e. 2-sequences, 2-periods, 2-treatments) for each specific population (i.e. self-reported Non Coeliac Gluten Sensitivity and Coeliac Disease subjects).

1 capsule of BL NCC 2705 or placebo will be given twice a day in the morning and in the evening with a meal over 2 periods of 4 days.

On day four a single dose of gluten (3g) will be administered and duodenal fluid will be collected in the following hours through a naso-intestinal catheter. The viability of BL NCC 2705, the production of serpin and its effects on gluten digestion and intestinal enzymatic activity will be determined.

No chronic administration of gluten as a challenge is foreseen in the study.

After a wash out period of minimum 2 weeks, period will be repeated.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Willing and able to sign written informed consent prior to trial entry
  • Male or female adults >18 years of age
  • For NCGS: self-reported gluten sensitivity with negative CD serology, on gluten free diet for at least 6 weeks with self-reported significant symptomatic improvement
  • For CD: confirmed serologic and histologic diagnosis of CD and on GFD for at least 12 months with self-reported significant symptomatic improvement
  • Body Mass Index (BMI) within the range >18 - <30 kg/m2
  • Willing and able to comply with study procedures and restrictions
  • In good health as determined by a medical history and medical examination

Exclusion criteria

  • Documented IgE-mediated food allergy
  • Subjects following an overly imbalanced or restrictive diet as per nutritional advice
  • Concurrent systemic disease and/or laboratory abnormalities considered by investigators to be detrimental for the participants safety or potentially interfering with the study procedures and/or study outcomes
  • Concurrent organic GI pathology other than benign polyps, diverticulosis, hemorrhoids, lipomas and melanosis coli
  • Previous abdominal surgery with the exception of hernia repair, appendectomy, caesarian section, tubal ligation, hysterectomy, hemorrhoidectomy
  • Patients who received antibiotics in the previous 2 weeks
  • women of childbearing potential not willing to use an effective contraception method

Treatment and study plan

Intervention 1 : BL NCC 2705 + Maltodextrin

Dietary Supplement

2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day

Intervention 1 : Maltodextrin

Other

2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day

Intervention 2 : BL NCC 2705 + Maltodextrin

Dietary Supplement

2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day

Intervention 2 : Maltodextrin

Other

2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day

Primary outcomes

  1. incidence, type and severity of adverse event

    Time frame: from Baseline to end of study (up to maximum 43 days)

    incidence, type and severity of adverse event

  2. Gastro-intestinal tolerability: visual analog scale

    Time frame: from Baseline to end of study (up to maximum 43 days)

    Sum of visual analog scale for gastro-intestinal symptoms assessment (nausea, vomiting, diarrhea, audible bowel sound, flatulence and abdominal cramping symptoms are assessed). Each scale is from 0 (no symptom) to 100mm (maximum symptom). The maximum sum value is 600.

Secondary outcomes

  1. Concentration of bacterial Serpin RNA and/or proteins (ng/mL) in duodenal aspirates

    Time frame: 19 sampling over 6h50 hours at visit 2 (day 4) and visit 3 (from day 22 to day 36)

    Measurements via RT-PRC and immuno-assay

  2. Concentration of Probiotic BL NCC 2705 (ng/mL) in duodenal aspirates

    Time frame: 19 sampling over 6h50 hours at visit 2 (day 4) and visit 3 (from day 22 to day 36)

    Measurements via PCR

  3. Concentration of gluten derived pepides in duodenal aspirates

    Time frame: 10 sampling over 3h30 at visit 2 (day 4) and visit 3 (from day 22 to day 36)

    Effect of BL NCC 2705 on gluten digestion based on the amount of gluten peptides detected in duodenal apsirates

  4. Concentration of gluten derived pepides in urine

    Time frame: 10 sampling over 3h30 at visit 2 (day 4) and visit 3 (from day 22 to day 36)

    Effect of BL NCC 2705 on gluten digestion based on the amount of gluten peptides detected in urine

  5. Level of elastase (Units/ mL) activity in duodenal aspirates

    Time frame: 19 sampling over 6h50 hours at visit 2 (day 4) and visit 3 (from day 22 to day 36)

    Measurements of proteolytic activity based assay

Sponsors and collaborators

Lead sponsor

Société des Produits Nestlé (SPN)

Industry

Registry information

Official study title

Proof of Concept Clinical Trial of Safety and Biological Activity of Bifidobacterium Longum NCC 2705 in Gluten Sensitivity

Important dates

Study start
2018
Primary completion
2019
Study completion
2020
First posted
Dec 14, 2018
Registry last updated
Dec 23, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.